Yukari Ishiguro

483 total citations
19 papers, 364 citations indexed

About

Yukari Ishiguro is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Yukari Ishiguro has authored 19 papers receiving a total of 364 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 9 papers in Oncology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Yukari Ishiguro's work include Bladder and Urothelial Cancer Treatments (3 papers), Cancer Mechanisms and Therapy (2 papers) and Cancer, Lipids, and Metabolism (2 papers). Yukari Ishiguro is often cited by papers focused on Bladder and Urothelial Cancer Treatments (3 papers), Cancer Mechanisms and Therapy (2 papers) and Cancer, Lipids, and Metabolism (2 papers). Yukari Ishiguro collaborates with scholars based in Japan and United States. Yukari Ishiguro's co-authors include Hitoshi Ishiguro, Hiroji Uemura, Mamoru Tsukuda, Yoshinobu Kubota, Hiroshi Miyamoto, Hideki Matsuda, Kyoko Fujita, Yukiko Yamashita, Takashi Kawahara and Mariko Kawakami and has published in prestigious journals such as Oncotarget, BMC Cancer and Cancers.

In The Last Decade

Yukari Ishiguro

18 papers receiving 359 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yukari Ishiguro Japan 12 148 138 91 86 59 19 364
Sachiko Moriyama Japan 10 221 1.5× 80 0.6× 68 0.7× 57 0.7× 73 1.2× 18 359
Shaolong Sun China 10 155 1.0× 132 1.0× 56 0.6× 70 0.8× 48 0.8× 21 331
Ayako Mitsuma Japan 13 189 1.3× 294 2.1× 122 1.3× 40 0.5× 41 0.7× 43 532
Hai Li China 9 130 0.9× 121 0.9× 110 1.2× 59 0.7× 56 0.9× 19 356
Grażyna Drabik Poland 14 134 0.9× 134 1.0× 100 1.1× 62 0.7× 117 2.0× 28 361
Hiroshi Hongo Japan 13 169 1.1× 119 0.9× 274 3.0× 80 0.9× 108 1.8× 74 511
Maddalena Grosso Italy 11 94 0.6× 76 0.6× 105 1.2× 89 1.0× 38 0.6× 31 315
Masayuki Shitara Japan 16 231 1.6× 150 1.1× 212 2.3× 50 0.6× 104 1.8× 30 464
Petros Giannikopoulos United States 8 213 1.4× 157 1.1× 212 2.3× 81 0.9× 70 1.2× 17 454
Miranda Versloot Netherlands 10 142 1.0× 97 0.7× 57 0.6× 113 1.3× 77 1.3× 19 459

Countries citing papers authored by Yukari Ishiguro

Since Specialization
Citations

This map shows the geographic impact of Yukari Ishiguro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yukari Ishiguro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yukari Ishiguro more than expected).

Fields of papers citing papers by Yukari Ishiguro

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yukari Ishiguro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yukari Ishiguro. The network helps show where Yukari Ishiguro may publish in the future.

Co-authorship network of co-authors of Yukari Ishiguro

This figure shows the co-authorship network connecting the top 25 collaborators of Yukari Ishiguro. A scholar is included among the top collaborators of Yukari Ishiguro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yukari Ishiguro. Yukari Ishiguro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Ishiguro, Yukari, Hisashi Hasumi, Masahiro Yamazaki, et al.. (2025). The Role of FGFR3 in the Progression of Bladder Cancer. Cancers. 17(21). 3588–3588.
2.
Yamasaki, K., Masahiro Uchida, Noriko Watanabe, et al.. (2022). Effects of antioxidant co‐supplementation therapy on spermatogenesis dysfunction in relation to the basal oxidation–reduction potential levels in spermatozoa: A pilot study. Reproductive Medicine and Biology. 21(1). e12450–e12450. 5 indexed citations
3.
Yasui, Masato, Takashi Kawahara, Koji Izumi, et al.. (2019). Androgen receptor mRNA expression is a predictor for recurrence-free survival in non-muscle invasive bladder cancer. BMC Cancer. 19(1). 331–331. 20 indexed citations
4.
Kawahara, Takashi, Yukari Ishiguro, Shinji Ohtake, et al.. (2018). PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer. BMC Urology. 18(1). 97–97. 44 indexed citations
5.
Ohtake, Shinji, Takashi Kawahara, Yukari Ishiguro, et al.. (2018). Oxidative stress marker 8-hydroxyguanosine is more highly expressed in prostate cancer than in benign prostatic hyperplasia. Molecular and Clinical Oncology. 9(3). 302–304. 20 indexed citations
6.
Kawahara, Takashi, Yukari Ishiguro, Meenal Sharma, et al.. (2018). Expression of receptor activator of nuclear factor kappa B ligand in bladder cancer. International Journal of Urology. 25(10). 901–902. 11 indexed citations
7.
Kawahara, Takashi, Yukari Ishiguro, Yasuhide Miyoshi, et al.. (2018). Expression of PD‐L1 and CTLA‐4 in female urethral carcinoma. IJU Case Reports. 2(1). 23–26. 1 indexed citations
8.
Ito, Yusuke, Aya Naiki‐Ito, Hiroyuki Kato, et al.. (2018). Chemopreventive effects of angiotensin II receptor type 2 agonist on prostate carcinogenesis by the down-regulation of the androgen receptor. Oncotarget. 9(17). 13859–13869. 11 indexed citations
9.
Ishiguro, Yukari, Hitoshi Ishiguro, & Hiroshi Miyamoto. (2013). Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition Up-regulates Interleukin-6 in Cancer Cells and Induces Subsequent Development of Interstitial Pneumonia. Oncotarget. 4(4). 550–559. 35 indexed citations
10.
Tsukuda, Mamoru, Norio Kondo, Yukari Ishiguro, et al.. (2011). Examination of the optimal condition on the in vitro sensitivity to telomelysin in head and neck cancer cell lines. Auris Nasus Larynx. 38(5). 589–599. 8 indexed citations
11.
12.
Kondo, Norio, Mamoru Tsukuda, Kyoko Fujita, et al.. (2010). Antitumor effects of telomelysin in combination with paclitaxel or cisplatin on head and neck squamous cell carcinoma.. PubMed. 23(2). 355–63. 13 indexed citations
13.
Horiuchi, Choichi, et al.. (2008). Correlation between FDG-PET findings and GLUT1 expression in salivary gland pleomorphic adenomas. Annals of Nuclear Medicine. 22(8). 693–698. 32 indexed citations
14.
Uemura, Hiroji, et al.. (2008). Angiotensin II Induces Oxidative Stress in Prostate Cancer. Molecular Cancer Research. 6(2). 250–258. 37 indexed citations
15.
Fujita, Kyoko, Daisuke Sano, Yukiko Yamashita, et al.. (2007). Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma. Oncology Reports. 18(1). 47–51. 51 indexed citations
16.
Ishiguro, Hitoshi, Yukari Ishiguro, Yoshinobu Kubota, & Hiroji Uemura. (2007). Regulation of prostate cancer cell growth and PSA expression by angiotensin II receptor blocker with peroxisome proliferator‐activated receptor gamma ligand like action. The Prostate. 67(9). 924–932. 38 indexed citations
17.
Yamashita, Yukiko, Yukari Ishiguro, Daisuke Sano, et al.. (2007). Antitumor effects of Nafamostat mesilate on head and neck squamous cell carcinoma. Auris Nasus Larynx. 34(4). 487–491. 16 indexed citations
18.
Sano, Daisuke, Mariko Kawakami, Kyoko Fujita, et al.. (2007). Antitumor effects of ZD6474 on head and neck squamous cell carcinoma. Oncology Reports. 14 indexed citations
19.
Sano, Daisuke, Hideki Matsuda, Yukari Ishiguro, et al.. (2006). Antitumor effects of IDN5109 on head and neck squamous cell carcinoma. Oncology Reports. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sachiko Moriyama Breakdown of academic impact, for papers by Shaolong Sun Breakdown of academic impact, for papers by Ayako Mitsuma Breakdown of academic impact, for papers by Hai Li Breakdown of academic impact, for papers by Grażyna Drabik Breakdown of academic impact, for papers by Hiroshi Hongo Breakdown of academic impact, for papers by Maddalena Grosso Breakdown of academic impact, for papers by Masayuki Shitara Breakdown of academic impact, for papers by Petros Giannikopoulos Breakdown of academic impact, for papers by Miranda Versloot
Rankless by CCL
2026